in similar groups of patients , the risk of developing proteinuria with auranofin therapy is significantly less than that with parenteral gold therapy ( p less than 0.05 ) and similar to that with background therapy with nonsteroidal antiinflammatory drugs ( p = 0.92 ) .
C0004320
auranofin
C0018026
gold